Plasmid VEGF therapy (Neovasculgen, pl-VEGF165) has an exceptional safety record spanning over a decade of clinical use.
Over 10,000 patients with PAD have already received VEGF therapy, and more than 210 patients have been monitored in post-marketing surveillance studies, establishing one of the most comprehensive safety databases for gene therapy products.